Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.
The pharmaceutical giant said Monday it will pay $229 in cash for each share of Seagen Inc. Pfizer then plans to let the biotech drug developer “continue innovating,” except with more resources than it would have alone, Pfizer Chairman and CEO Albert Bourla told analysts.
Cancer treatments are a priority for Pfizer. They brought in $12 billion in revenue for the drugmaker last year. But Pfizer has only marketed a couple first-generation ADC treatments, a spokeswoman said. Seagen’s top seller, Adcetris, treats lymph system cancers. It brought in $839 million in sales last year, a 19% increase over the previous year.
Bourla said earlier this year that the company planned to use its “extraordinary firepower” to buy products that will deliver $25 billion in incremental revenue by 2030.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer Agrees to Buy Seagen for $43 BillionThe New York drugmaker would pay $229 a share in cash for the biotech company and its pioneering cancer treatments.
Weiterlesen »
Pfizer looks beyond COVID sales with $43 bln deal for cancer drugmaker SeagenPfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Weiterlesen »
Pfizer to buy cancer drugmaker Seagen for $43 billionNEW: Pfizer said it has agreed to buy cancer drugmaker Seagen for $43 billion in cash. It's the largest pharma deal since Abbvie bought Allergan in 2020.
Weiterlesen »
Pfizer buys Seagen for $43B, boosts access to cancer drugsPfizer will spend $43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay $229 per Seagen share.
Weiterlesen »
Pfizer looks past COVID with $43 bln deal for cancer drug innovator SeagenPfizer Inc struck a $43 billion deal for Seagen Inc to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers.
Weiterlesen »
Pfizer to buy Seagen for $43B to enhance reach of cancer drugsDrugmaker seeks out new revenue sources as expiration of patents protecting drugs like Ibrance from competition nears.
Weiterlesen »